Logo of Memphasys (ASX:MEM)Latest Memphasys (ASX:MEM) News

Page 5
Page 5 of 7

Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.
Logan Eniac
25 Jan 2026

Memphasys Hits $102K Revenue Milestone After CE Mark Approval

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.
Ada Torres
22 Jan 2026

Memphasys Secures Vital Convertible Note Extension with Peters Investments

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.
Ada Torres
30 Dec 2025

Memphasys Raises $1.12M to Accelerate Felix™ System Expansion in Europe and MENA

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.
Ada Torres
30 Dec 2025

Memphasys Unlocks A$50M Market with CE Mark for Felix™ System

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.
Ada Torres
29 Dec 2025

Memphasys Secures €525K Deal to Enter Italian IVF Market

Memphasys has inked a five-year supply agreement with Italy’s Centro Fertilita Assistita, marking its first major European contract and setting the stage for broader adoption of its Felix™ sperm isolation system.
Ada Torres
22 Dec 2025

Memphasys’ Felix™ Scores Early 500-Cartridge Order Ahead of CE Mark

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.
Ada Torres
18 Dec 2025

Memphasys Reshapes Leadership to Accelerate Global Sales of Felix™ System

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.
Ada Torres
10 Dec 2025

Memphasys Accelerates Felix™ Sales Push in Middle East Ahead of CE Mark

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.
Ada Torres
8 Dec 2025

Memphasys Secures $1.12M to Propel Felix™ System into Global Markets

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.
Ada Torres
10 Nov 2025

Memphasys Accelerates Felix™ Rollout with Expanded MENA Deal and Cost Cuts

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.
Ada Torres
31 Oct 2025

Memphasys Secures Key Indian Supply Deal to Boost IVF Market Growth

Memphasys has signed a pivotal supply agreement with Andro Diagnostics to distribute its Felix™ sperm separation system across over 200 IVF clinics in India, marking a major step in its new global go-direct commercial strategy.
Ada Torres
28 Oct 2025